Essential role of mitochondrial Ca2+-activated and ATP-sensitive K+ channels in sildenafil-induced late cardioprotection

Journal of Molecular and Cellular Cardiology

Volumn 44, Issue 1, 2008, Pages 105-113

  Wang, Xiaoyin ^a   Fisher, Patrick W ^a   Xi, Lei ^a   Kukreja, Rakesh C ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardioprotection; Ischemia reperfusion; Phosphodiesterase inhibitor; Potassium channel; Small interfering RNA

Indexed keywords

5 HYDROXYDECANOIC ACID; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; CALCIUM ACTIVATED POTASSIUM CHANNEL; CALCIUM ION; MITOCHONDRIAL ENZYME; PAXILLINE; POTASSIUM ION; SILDENAFIL; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA CHAIN; CELL DEATH; HEART INFARCTION; HEART INFARCTION SIZE; HEART MITOCHONDRION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; ISOLATED HEART; KNOCKOUT GENE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION INJURY; UPREGULATION; WESTERN BLOTTING;

ANIMALS; CARDIOTONIC AGENTS; CORONARY CIRCULATION; GENE EXPRESSION REGULATION; HEART FUNCTION TESTS; HEART VENTRICLES; MALE; MICE; MICE, INBRED ICR; MITOCHONDRIA, HEART; MYOCARDIAL CONTRACTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PIPERAZINES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; POTASSIUM CHANNELS, CALCIUM-ACTIVATED; PURINES; RECOVERY OF FUNCTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SULFONES; VASODILATOR AGENTS;

MUS;

EID: 37549014219     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2007.10.006     Document Type: Article

References (48)

1. Corbin J.D., Francis S.H., and Webb D.J. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology 60 2 Suppl 2 (2002) 4-11
2. Sebkhi A., Strange J.W., Phillips S.C., Wharton J., and Wilkins M.R. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation 107 (2003) 3230-3235
3. Kukreja R.C., Salloum F., Das A., Ockaili R., Yin C., Bremer Y.A., et al. Pharmacological preconditioning with sildenafil: basic mechanisms and clinical implications. Vascul Pharmacol 42 (2005) 219-232
4. ATP channels in rabbits. Am J Physiol Heart Circ Physiol 283 (2002) H1263-H1269
5. Salloum F., Yin C., Xi L., and Kukreja R.C. Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res 92 (2003) 595-597
6. Das A., Xi L., and Kukreja R.C. Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem 280 (2005) 12944-12955
7. Fisher P.W., Salloum F., Das A., Hyder H., and Kukreja R.C. Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 111 (2005) 1601-1610
8. + channels. Possible mechanism of cardioprotection. Circ Res 81 (1997) 1072-1082
9. + channels and myocardial preconditioning. Circ Res 84 (1999) 973-979
10. ATP channels triggers the preconditioned state by generating free radicals. Circ Res 87 (2000) 460-466
11. + channel for cardiac protection against ischemic injury is dependent on protein kinase C activity. Circ Res 85 (1999) 731-741
12. 2+ overload during simulated ischemia and reperfusion: possible mechanism of cardioprotection. Circ Res 89 (2001) 891-898
13. + channels in the cardiac inner mitochondrial membrane. Science 298 (2002) 1029-1033
14. Cao C.M., Xia Q., Gao Q., Chen M., and Wong T.M. Calcium-activated potassium channel triggers cardioprotection of ischemic preconditioning. J Pharmacol Exp Ther 312 (2005) 644-650
15. + channels is involved in ischemic preconditioning in canine hearts. J Mol Cell Cardiol 37 (2004) 1213-1218
16. + channels triggers early and delayed preconditioning against I/R injury independent of NOS in mice. Am J Physiol Heart Circ Physiol 287 (2004) H2070-H2077
17. Brenner R., Perez G.J., Bonev A.D., Eckman D.M., Kosek J.C., Wiler S.W., et al. Vasoregulation by the beta1 subunit of the calcium-activated potassium channel. Nature 407 (2000) 870-876
18. Ca, a unique member of the voltage-gated K channel superfamily. News Physiol Sci 13 (1998) 112-117
19. + channels in cardiac mitochondria. Am J Physiol Heart Circ Physiol 289 (2005) H1635-H1642
20. Patterson A.J., Henrie-Olson J., and Brenner R. Vasoregulation at the molecular level: a role for the beta1 subunit of the calcium-activated potassium (BK) channel. Trends Cardiovasc Med 12 (2002) 78-82
21. Shieh C.C., Coghlan M., Sullivan J.P., and Gopalakrishnan M. Potassium channels: molecular defects, diseases, and therapeutic opportunities. Pharmacol Rev 52 (2000) 557-594
22. 2+ spark/STOC coupling and elevated blood pressure. Circ Res 87 (2000) E53-E60
23. Senti M., Fernandez-Fernandez J.M., Tomas M., Vazquez E., Elosua R., Marrugat J., et al. Protective effect of the KCNMB1 E65K genetic polymorphism against diastolic hypertension in aging women and its relevance to cardiovascular risk. Circ Res 97 (2005) 1360-1365
24. + channels in the protective effect of ACE inhibition against ischemic myocardial injury. Hypertension 31 (1998) 1290-1298
25. 2 constriction of the rabbit ductus arteriosus by inhibiting type 5 phosphodiesterase and activating BKCa channels. Pediatr Res 52 (2002) 19-24
26. Archer S.L., Gragasin F.S., Webster L., Bochinski D., and Michelakis E.D. Aetiology and management of male erectile dysfunction and female sexual dysfunction in patients with cardiovascular disease. Drugs Aging 22 (2005) 823-844
27. Gragasin F.S., Michelakis E.D., Hogan A., Moudgil R., Hashimoto K., Wu X., et al. The neurovascular mechanism of clitoral erection: nitric oxide and cGMP-stimulated activation of BKCa channels. FASEB J 18 (2004) 1382-1391
28. Hannon G.J. RNA interference. Nature 418 (2002) 244-251
29. Yin C., Xi L., Wang X., Eapen M., and Kukreja R.C. Silencing heat shock factor 1 by small interfering RNA abrogates heat shock-induced cardioprotection against ischemia-reperfusion injury in mice. J Mol Cell Cardiol 39 (2005) 681-689
30. Xi L., Salloum F., Tekin D., Jarrett N.C., and Kukreja R.C. Glycolipid RC-552 induces delayed preconditioning-like effect via iNOS-dependent pathway in mice. Am J Physiol 277 (1999) H2418-H2424
31. Shi Y., Rafiee P., Su J., Pritchard Jr. K.A., Tweddell J.S., and Baker J.E. Acute cardioprotective effects of erythropoietin in infant rabbits are mediated by activation of protein kinases and potassium channels. Basic Res Cardiol 99 (2004) 173-182
32. Joyeux-Faure M., Ramond A., Beguin P.C., Belaidi E., Godin-Ribuot D., and Ribuot C. Early pharmacological preconditioning by erythropoietin mediated by inducible NOS and mitochondrial ATP-dependent potassium channels in the rat heart. Fundam Clin Pharmacol 20 (2006) 51-56
33. Brayden J.E., and Nelson M.T. Regulation of arterial tone by activation of calcium-dependent potassium channels. Science 256 (1992) 532-535
34. Nelson M.T., and Quayle J.M. Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol 268 (1995) C799-C822
35. + channels and dilation in small, resistance-size arteries. Mol Pharmacol 72 (2007) 359-369
36. + channels as therapeutic drug targets. Pharmacol Ther 94 (2002) 157-182
37. + channels in cardiac myocytes: a mechanism of the cardioprotective effect and modulation by protein kinase A. Circulation 111 (2005) 198-203
38. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., and Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001) 494-498
39. Bridge A.J., Pebernard S., Ducraux A., Nicoulaz A.L., and Iggo R. Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 34 (2003) 263-264
40. Sledz C.A., Holko M., de Veer M.J., Silverman R.H., and Williams B.R. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 5 (2003) 834-839
41. Booz G.W., Day J.N., and Baker K.M. Interplay between the cardiac renin angiotensin system and JAK-STAT signaling: role in cardiac hypertrophy, ischemia/reperfusion dysfunction, and heart failure. J Mol Cell Cardiol 34 (2002) 1443-1453
42. Kodama H., Fukuda K., Pan J., Makino S., Baba A., Hori S., et al. Leukemia inhibitory factor, a potent cardiac hypertrophic cytokine, activates the JAK/STAT pathway in rat cardiomyocytes. Circ Res 81 (1997) 656-663
43. Pan J., Fukuda K., Kodama H., Makino S., Takahashi T., Sano M., et al. Role of angiotensin II in activation of the JAK/STAT pathway induced by acute pressure overload in the rat heart. Circ Res 81 (1997) 611-617
44. Lincoln T.M., Komalavilas P., and Cornwell T.L. Pleiotropic regulation of vascular smooth muscle tone by cyclic GMP-dependent protein kinase. Hypertension 23 (1994) 1141-1147
45. + channel, Hslo, is a target of cGMP-dependent protein kinase phosphorylation in vivo. J Biol Chem 273 (1998) 32950-32956
46. Fukao M., Mason H.S., Britton F.C., Kenyon J.L., Horowitz B., and Keef K.D. Cyclic GMP-dependent protein kinase activates cloned BKCa channels expressed in mammalian cells by direct phosphorylation at serine 1072. J Biol Chem 274 (1999) 10927-10935
47. Sasaki N., Sato T., Ohler A., O'Rourke B., and Marban E. Activation of mitochondrial ATP-dependent potassium channels by nitric oxide. Circulation 101 (2000) 439-445
48. Fernandez-Fernandez J.M., Tomas M., Vazquez E., Orio P., Latorre R., Senti M., et al. Gain-of-function mutation in the KCNMB1 potassium channel subunit is associated with low prevalence of diastolic hypertension. J Clin Invest 113 (2004) 1032-1039